- Home
- » Tags
- » Sulfonylurea
Top View
- Use of Exenatide and Liraglutide in Denmark: a Drug Utilization Study
- New Drug Evaluation: Albiglutide Month/Year of Review: January
- Scientific Presentations of Exenatide Data Show Significant
- Sulfonylurea Overdose in Children
- Liraglutide (Victoza)
- American Diabetes Association Treatment Algorithm for Type 2 Diabetes
- Sulfonylureas Rapidly Cross Phospholipid Bilayer Membranes by a Free-Diffusion Mechanism Frits Kamp,1 Nadeem Kizilbash,1 Barbara E
- What's Next After Metformin? Focus on Sulphonylurea: Add-On Or Combination Therapy
- BYETTA (Exenatide) Injection Hemodialysis and Kidney Transplantation
- Albiglutide (TANZEUM) Drug Monograph
- GLP-1 Receptor Agonists (Byetta /Victoza ) Step Therapy Criteria
- Antidiabetic Medication and Risk of Dementia in Patients with Type 2 Diabetes: a Nested Case–Control Study
- Comparative Safety and Efficacy of Glibenclamide in the Elderly
- Dipeptidyl Peptidase-4 Inhibitor Compared with Sulfonylurea in Combination with Metformin: Cardiovascular and Renal Outcomes In
- Rifamycins and Anti-Diabetic Agents: Drug-Drug Interactions
- Modern Sulfonylureas: Dangerous Matthew C
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists a Review of Their Efficacy and Tolerability
- Comparison of Insulin Degludec/Insulin
- Safety Evaluation of Adverse Reactions in Diabetes S
- Victoza, INN-Liraglutide
- Inhibition of Vasopressin-Stimulated Prostaglandin E Biosynthesis by Chlorpropamide in the Toad Urinary Bladder
- Type 2 Diabetes: Options After Metformin Pankaj Shah, MD Division of Endocrinology, Metabolism, Nutrition and Diabetes Mayo Clinic, Rochester, MN
- The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: an Empirical Perspective from Experience in Australia
- Association Between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
- Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: a Disproportionality Analysis in the World Health Organization Vigibase
- Type 2 Diabetes, but Not Insulin (Analog)
- Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
- Overview of the Antidiabetic Agents
- GLP-1 (Glucagon-Like Peptide-1) ® Agonists (Adlyxin™, Byetta , Bydureon™, Tanzeum™, Trulicity™, Victoza®)
- Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: an Open-Cohort Study of ∼130,000 Swedish Subjects Over 14 Years
- 1446.Full.Pdf
- Glipizide Extended Release Tablets for Oral Use
- CP.CPA.16 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- Victoza Pi 9 Page 1 of 26 AUSTRALIAN PRODUCT
- Risk Assessment and Risk Mitigation Review(S)
- Once-Weekly GLP-1 Receptor Agonists for the Management Of
- Oral Diabetes Medications
- DESCRIPTION Tolbutamide Is an Oral Blood-Glucose-Lowering Drug of the Sulfonylurea Class
- Glibenclamide Targets Sulfonylurea
- [3H]Glibenclamide-Binding Protein, a Putative Neuronal
- Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
- Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St
- Albiglutide) for Injection, for Subcutaneous Use Reaction to Albiglutide Or Any of the Product Components
- Victoza (Liraglutide) Injection
- Exploring the Substitution of Exenatide for Insulin in Patients with Type 2 Diabetes Treated with Insulin in Combination with Oral Antidiabetes Agents
- Drug Class Review on Oral Hypoglycemics
- Sulfonylureas and the Risks of Cardiovascular Events and Death
- Tolbutamide PI
- GLUCOTROL® (Glipizide) TABLETS for Oral Use
- Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride As
- Pharmacologically Relevant Drug Interactions of Glucagon-Like Peptide-1 Receptor Agonists
- Annex I Summary of Product Characteristics
- Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit P70s6k Activity and Upregulate KLF4
- Glynase (Glyburide) Tablet Label
- 125431Orig1s000